Cadence to raise $86.6 million in financing

Cadence Pharmaceuticals, a biopharmaceutical company, has entered into an agreement to issue and sell in a private placement approximately 12 million shares of the company's common stock and warrants to purchase up to approximately six million additional shares of the company's common stock, for aggregate gross proceeds of approximately $86.6 million.